EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN
Value in Health · 2026-06 · 29 (6) · S130
DOI: 10.1016/j.jval.2026.03.648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Akira Yuasa und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Yuasa, A., Nagano, M., Kamei, Y., Hatsuyama, K., Matsuda, H., Hlavacek, P., Dibonaventura, M., & Suzuki, K. (2026). EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN. Value in Health, 29(6), S130. https://doi.org/10.1016/j.jval.2026.03.648
Vancouver
Yuasa A, Nagano M, Kamei Y, Hatsuyama K, Matsuda H, Hlavacek P, et al. EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN. Value in Health. 2026;29(6):S130. doi:10.1016/j.jval.2026.03.648
BibTeX
@article{Yuasa2026,
author = {Yuasa, Akira and Nagano, Mitsuhiro and Kamei, Yoichi and Hatsuyama, Kengo and Matsuda, Hiroyuki and Hlavacek, Patrick and Dibonaventura, Marco and Suzuki, Kenshi},
title = {EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S130},
doi = {10.1016/j.jval.2026.03.648}
}
EUVIMED